Recently, many studies revealed that the dysregulation of SIRT2 activity is a key factor contributing to the pathogenesis of cancer [24], neurodegenerative diseases [25,26], type II diabetes [27], and bacterial infections [21,23], which makes SIRT2 a promising target for pharmaceutical intervention. The gene discussed is SIRT2; the disease is neurodegenerative disease.